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ABSTRACT
Background/aims This study aimed to investigate
treatment patterns and medication adherence of
glaucoma. It also identiﬁed key factors associated with
non-adherence.
Methods It was a cross-sectional, observational study.
Patients who use eye-drops for ≤2 years were recruited
at 15 eye clinics from March to November 2013. Data
were collected through self-administered questionnaires
and medical chart review. Medication adherence was
evaluated using patients’ self-report on pill count and
deﬁned as patients’ administering drug for ≥80% of
prescribed days. Medication adherence rate was
calculated by dividing actual number of administration
from total prescribed number of administration for
7 days. Patients whose self-reported prescription was
different from total daily doses of physicians’ prescription
were considered as non-adherent.
Results A total of 1050 patients included, and
medication adherence rate was evaluated in 1046
patients whose veriﬁcation of adherence was available.
Of the total, 27.4% were non-adherent, and the
medication adherence rates of the total, the adherent,
and the non-adherent were 90.6±17.8%, 96.8±5.5%
and 56.6±24.7%, respectively. The most commonly used
medication was prostaglandin (PGA) alone and the
second was combination of two-class (β-blocker and
carbonic anhydrase inhibitor (CAI)) and three-class
combination of PGA, β-blocker and CAI followed. In
multivariate analysis, the risk of non-adherence was
1.466 times greater in males than in females (95% CI
1.106 to 1.943) and 1.328-fold greater as the daily
number of administration was increased (95% CI 1.186
to 1.487).
Conclusion Approximately, one-third of the patients
were non-adherent, and males and increased daily
number of administration were associated with non-
adherence. It highlights that more systematic treatment
strategies should be considered for better medication
adherence, leading to effective glaucoma management.
INTRODUCTION
Glaucoma is one of the world’s three major causes
of blindness, which is a common disease that affects
more than 70 million people worldwide.1 By 2020,
the number of patients with glaucoma is expected
to reach 37 million in Asia, which represents 47%
of the world’s population with glaucoma.1 In South
Korea, 400 000 individuals reported that they were
on glaucoma therapy in 2009 alone, with an annual
increase rate of 10% on average, which means that
0.8% of the total population were being treated for
glaucoma in 2009.2 However, the actual number of
patients with glaucoma is estimated to be several
times higher.
Lowering intraocular pressure (IOP) has been
shown to be an effective and proven treatment to
prevent damage to the optic nerve. Current
methods used to lower IOP are topical medication
(eye-drops), laser therapy and glaucoma surgery.3 A
randomised clinical study showed that glaucoma
treatment using eye-drops signiﬁcantly lowers the
IOP and slows the progression of disease.4 To
improve treatment outcomes of topical
IOP-lowering agents, various factors must be con-
sidered. Medication adherence is one of the
important factors that signiﬁcantly affect the
outcome of glaucoma treatment.5
Medication adherence plays an essential role
alongside other factors such as efﬁcacy, stability,
cost of the drug and quality of life of a patient.6
Eye-drops can be inconvenient to self-administer
and patients sometimes do not use them at the right
times of day or in the right doses.7 According to a
study conducted on 581 patients with glaucoma,
only 60% of the patients used their eye-drops as
prescribed by their physicians, with the most
common reasons for non-adherence being forget-
fulness, being busy and negligence.8 Medication
adherence has been known to be affected by a
number of other factors, such as age, education
level, glaucoma severity,5 9 drug class,6 dosage
regimen,10 side effects,10 drug costs,8 the fear of
blindness,11 disease awareness11 and amnesia.12
When medication adherence was assessed every
6 months using retrospective insurance claims data,
it was found that adherence declined steadily
during the 3-year observation period.5 Medication
adherence in the third year was reported to be a
mere 15%–58% depending on drug class; medica-
tion adherence of patients prescribed prostaglandins
(PGAs) was the highest, followed by β-blockers,
α-antagonists and carbonic anhydrase inhibitors
(CAIs) (the last two showed similar adherence).5
Although the importance of medication adher-
ence in glaucoma treatment has been proven by
various studies, only a few studies on domestic
glaucoma treatment status and patient medication
adherence were available, which resulted in a lack
of the basic data necessary for the proper care and
effective management of treatment in South Korea.
Since treatment status and medication adherence
are likely to be affected by a country’s unique
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health insurance system, culture and social atmosphere, this
study aimed to investigate those elements in a clinical setting in
South Korea, identify the key factors that affect patient adher-
ence, and ultimately provide a foundation to improve overall
glaucoma treatment outcomes in South Korea.
MATERIALS AND METHODS
Patients
This was a non-interventional, multicentre, cross-sectional
observational study conducted in 15 nationwide medical institu-
tions located in in South Korea. The study subjects were outpati-
ents diagnosed with glaucoma who were at least 20 years old,
received treatment via eye-drops, had been treated for at least
1 month but <2 years and who all gave written consent to par-
ticipate in the study. We excluded patients who were hospitalised
for glaucoma treatment just before data collection, those who
had serious or unstable medical conditions and any other
patients who were determined by physicians that they should be
excluded from the data collection process for any other reasons.
Data collection
During patients’ regular visit, the investigators in all medical
institutions selected and enrolled their study patients from those
who met all the selection criteria. All questionnaires were col-
lected from the patients via interviews in each medical institu-
tion. Data on demographic, clinical characteristics and drug
habits were collected through patients’ self-reported question-
naires and medical chart review.
The collected demographic data were gender, age, education
level, and occupational status. The data on clinical character-
istics were the following: types of glaucoma, duration of the
disease, severity of the disease (Hodapp-Parrish-Anderson cri-
teria: mild (mean deviation ≥−6 dB); moderate (mean deviation
<−6 dB but >−12 dB) or severe (mean deviation ≤−12 dB)),
family history of glaucoma, history of glaucoma surgery and
presence of underlying conditions. Furthermore, the types of
medications prescribed were examined to investigate the treat-
ment patterns. Additionally, the presence or absence of assist-
ance by another person during administration of eye-drops was
recorded.
Medication adherence
Medication adherence rate was calculated using the following
formula:
Medication
adherencerate ð%Þ ¼
Daily totalnumber
ofprescription
doses
7days
0
B@
1
CA
Numberofprescription
doses thatwasmissed
duringthe pastweek
Weekly totalnumberof prescriptiondoses foreyedrops 100
*Daily total number of prescription doses×7
Total number of eye-drop administrations per week was veri-
ﬁed by multiplying the patient-reported daily total number of
prescription doses for eye-drops by 7 days; the number of times
the patients missed to administer his/her eye-drops during the
last 7 days was assessed through patient questionnaires. The
latter was subtracted from the total number of prescription
doses for a week, and the resulting value was divided by the
total number of prescription doses for a week, which was then
multiplied by 100 to calculate the medical adherence rate in per-
centage. ‘Being adherent’ to the prescribed medication was
deﬁned as an adherence of ≥80%, and ‘being non-adherent’
was deﬁned as adherence of <80%.13 Furthermore, if the data
on the total number of daily doses prescribed by the physician
were different from the patients’ reports, the patient was consid-
ered not to be following the prescription and was therefore cate-
gorised as ‘being non-adherent’.
Statistical analysis
Descriptive analysis was performed for the basic features of the
data as in mean with SD for continuous variables and frequency
(n) and percentage (%) for categorical variables. For medication
adherence, its differences were compared according to epi-
demiological characteristics and treatment patterns. Based on
variable types and normality, χ2 test, Student’s t-test and
Mann-Whitney U test were used to examine differences.
To examine factors associated with non-adherence, logistic
regression analysis was used. Primarily, the overall impact of the
independent variables was examined by entering all independent
variables into the regression model and, secondarily, backward
elimination analysis was performed by adjusting gender and age
as ﬁxed variables. To evaluate the appropriateness of the back-
ward elimination analysis model, Hosmer-Lemeshow’s
goodness-of-ﬁt test was performed and the model was deemed
to be appropriate at a signiﬁcance level with p>0.05. All statis-
tical analyses were performed using PASW Statistics V.20.0
(SPSS, Chicago, Illinois, USA), and all p values obtained from
statistical analyses were the results of two-sided tests, in which
the statistical signiﬁcance level was set at p<0.05.
RESULTS
Patient characteristics
Of a total of 1050 patients with glaucoma, 54.8% (575 patients)
were males, 10% more males than females, and the average age
was 55.1 years old (SD ±12.9); 73.6% (773 patients) were
<65 years old. When the education level of the patients was
divided into two groups—less than or equal to high school gradu-
ation and more than high school graduation—a similar portion of
patients were found to be present in each group. About 60%
patients were reported to be employed at the time of data collec-
tion. The most common type of glaucoma was normal-tension
accounting for 62.4% (655 patients), followed by primary open-
angle glaucoma (33.2%, 349 patients) and primary angle-closure
glaucoma (4.2%, 44 patients); two patients with secondary glau-
coma were also included in the study. The average disease duration
from the date of diagnosis was 13.6 months (SD ±15.6). Patients
with mild glaucoma (mean deviation ≥−6 dB) were most
common, representing 54.6% (573 individuals), and patients with
moderate (mean deviation <−6 dB but > −12 dB) and severe
(mean deviation ≤−12 dB) glaucoma made up 18.1% (190
patients) and 21% (221 patients), respectively. Less than 10% of
the total had either a family history of glaucoma or a history of
glaucoma surgery, and approximately one-third of the patients had
underlying diseases. Regarding medication characteristics, the
average daily medication frequency for all patients was 1.9 times
(SD ±1.1), the average number of prescribed eye-drops was 1.3
(SD ±0.5) and 17.2% of the patients (181 patients) had helpers
for the administration of eye-drops (table 1).
Treatment features
Treatment patterns were categorised according to the classes of
the eye-drops administered. Administration of PGA alone was
the most common treatment method, used in 43.5% of the
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study population (457 patients); 17.1% (180 patients) were
administered both a β-blocker and a CAI, and 9.1% (101
patients) were being treated with the three classes, PGA,
β-blocker, and CAI (ﬁgure 1).
Patients with normal-tension glaucoma and primary open-angle
glaucoma were most commonly prescribed PGA alone, while
those with primary angle-closure glaucoma were most commonly
prescribed the two classes of a β-blocker and CAI. Regardless of
disease severity, disease duration (either ≤12 months or
>12 months) and the presence of underlying disease, PGA alone
was the most common treatment. Among the patients who had a
history of glaucoma surgery, the proportion of patients prescribed
both a β-blocker and CAI together was the highest, which was fol-
lowed by patients given PGA alone (ﬁgure 2).
Medication adherence
Medication adherence of 1046 patients was evaluated excluding
4 patients for whom veriﬁcation of adherence was not available.
Among those, 72.6% (759 patients) were adherent, while
27.4% were non-adherent to their eye-drops. And 14.7% (154
patients) whose self-reported number of daily instillation was
not consistent with daily dose of physicians’ prescription were
excluded for the assessment of medication adherence rate. The
mean medication adherence rates of the total, the adherent and
the non-adherent were 90.6% (SD 17.8), 96.8% (SD 5.5) and
56.6% (SD 24.7), respectively (table 2).
Thus, there was an approximately 40% difference in the
medication adherence rate between the adherent and non-
adherent patients (table 2). In univariate analysis of adherent
and non-adherent patients, depending on patient characteristics,
males tended to be more non-adherent than females (OR 1.505,
95% CI 1.140 to 1.987) (table 3).
Patients either on non-PGA monotherapy or on any combin-
ation therapy tended to be more non-adherent than those given
PGA monotherapy (OR 1.953, 95% CI 1.200 to 3.177 and OR
1.480, 95% CI 1.107 to 1.979, respectively) (table 4).
Also, the risk of non-adherence was higher as the prescribed
frequency of administration was increased (OR 1.321, 95% CI
1.182 to 1.477) and also as the number of medications was
increased (OR 1.603, 95% CI 1.287 to 1.995) (table 4). In
multivariate analysis using backward elimination, the risk of
non-adherence was shown to be greater in males than in females
by 1.466-fold (95% CI 1.106 to 1.943) and also greater as the
prescribed frequency of administration was increased by
1.328-fold (95% CI 1.186 to 1.487) (table 5).
DISCUSSION
Although the medication adherence of patients with glaucoma
differs between reports, depending on the study patients and
the methods of measurement, it is known to be low because
glaucoma typically has no clear symptoms until it develops
enough to reach its last stages.1 Therefore, an increase in medi-
cation adherence is regarded as an important factor for the
better management of glaucoma. In this multicentre study, we
aimed to investigate which factors inﬂuence medication adher-
ence among patients with glaucoma in South Korea.
According to our results, the medication adherence rate of
the patients with glaucoma in South Korea was 90.6±17.8%,
and patients with <80% medication adherence (non-adherent
patients) made up about 30% of the study population. Hence,
medication adherence of patients with glaucoma in South Korea
appears to be relatively good when compared with that in
foreign countries as reported to be 15%–58%.5 And, it could be
partially explained by the relatively good insurance coverage
and accessibility; also, however, we used self-reported question-
naires to quantify medication adherence rate, which may play a
role to bring these results.
In this study, the risk of non-adherence was found to be
higher among males and as the daily prescribed frequency of
eye-drop administration increased. The latter result is consistent
with the ﬁndings of a study, which showed that medication
adherence of patients administered PGA alone was the highest;
that study used retrospective insurance claims for prescription
eye-drop reﬁlls, measured every 6 months.5 Therefore, continu-
ous education and efforts to simplify the drug administration
method are needed for those who are at increased risk to
enhance the therapeutic effect of glaucoma treatment and
improve medication adherence.
This study did not show differences in adherence by type of
glaucoma. It is known that patients with angle-closure glaucoma
would be more adherent to their medication regimens given the
fact that angle-closure glaucoma is often accompanied by
Table 1 Patients’ characteristics
n=1050 %
Sex
Male 575 54.8
Female 475 45.2
Age (years)* 55.1±12.9
<65 773 73.6
≥65 277 26.4
Education level
≥High school graduation 526 50.1
<High school graduation 524 49.9
Employment
Yes 613 58.4
No 437 41.6
Glaucoma types
Normal tension 655 62.4
Open angle 349 33.2
Angle closure 44 4.2
Others 2 0.2
Disease duration (months)* 13.6±15.6
≤12 550 52.4
>12 500 47.6
Visual field defect severity
Mild 573 54.6
Moderate 190 18.1
Severe 221 21.0
No data 66 6.3
Glaucoma family history
Yes 80 7.6
No 970 92.4
Glaucoma surgery
Yes 36 3.4
No 1014 96.6
Underlying disease
Yes 368 35.0
No 682 65.0
Daily number of instillation* 1.9±1.1
Number of eye-drops* 1.3±0.5
Helper/assistant
No 181 17.2
Yes 867 82.6
*Mean±SD.
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Figure 1 Treatment patterns.
Figure 2 Top 3 prescribed glaucoma medication by patients’ clinical characteristics.
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symptoms. However, this study result did not show the differ-
ence in medication adherence by types of glaucoma. It may have
been difﬁcult to detect the signiﬁcant difference in patients with
different glaucoma types given this study include just few angle-
closure patients (4.2%, 44 patients).
This study was a large-scale observational study, in which
>1000 patients with glaucoma from nationwide medical institu-
tions were enrolled; thus, it provides epidemiological data repre-
sentative of Korean population with glaucoma. Therefore, the
study results can be used to help understand the characteristics and
treatment patterns of patients with glaucoma in real hospital set-
tings. Furthermore, considering that this study targeted patients
whose duration of treatment was relatively short (patients with a
treatment period of at least 1 month but <2 years), it can be a
good source to reinforce treatment strategies for long-term disease
management as it disclosed patients’ features in the early stages of
disease management. In addition, the associated factors affecting
non-adherence to administration of eye-drops were identiﬁed, so
Table 2 Adherence to prescribed glaucoma medications
Non-adherent patients
Total patients* Adherent patients† Absolute non-adherent‡ Misconception§
n (%) 1046 759 (72.6) 133 (12.7) 154 (14.7)
Mean±SD 90.6±17.8 96.8±5.5 56.6±24.7 NA
Minimum, maximum 0, 100 82.1, 100 0, 78.6 NA
*Excluded four patients whose adherence could not be calculated.
†Adherent rate ≥80%.
‡Adherent rate <80%.
§Patients whose reported number of daily instillation was not consistent with daily dose of prescription.
Table 3 Medication non-adherence according to patients’ characteristics
Variables Adherent (n=759) Non-adherent (n =287) OR p Value
Sex
Male 395 (68.9) 178 (31.1) 1.505 (1.140 to 1.987) 0.004
Female 364 (77.0) 109 (23.0) 1
Age (years)
<65 551 (71.5) 220 (28.5) 1.240 (0.903 to 1.701) 0.183
≥65 208 (75.6) 67 (24.4) 1
Surgery history
Yes 22 (61.1) 14 (38.9) 1.718 (0.867 to 3.406) 0.117
No 737 (73.0) 273 (27.0) 1
Family history
Yes 63 (78.8) 17 (21.3) 1 0.197
No 696 (72.0) 270 (28.0) 1.438 (0.826 to 2.501)
Employment
Yes 431 (70.5) 180 (29.5) 1.280 (0.968 to 1.692) 0.082
No 328 (75.4) 107 (24.6) 1
Education level
>High school graduation 373 (70.9) 153 (29.1) 1.182 (0.900 to 1.551) 0.229
≤High school graduation 386 (74.2) 134 (25.8) 1
Glaucoma types*
Normal tension 484 (74.3) 167 (25.7) 0.802 (0.601 to 1.070) 0.198
Angle closure 29 (65.9) 15 (34.1) 1.202 (0.619 to 2.335)
Open angle 244 (69.9) 105 (30.1) 1
Disease duration† 13.67±15.13
12 (6, 19)
13.67±17.03
12 (6, 18)
1.000 (0.991 to 1.009) 0.896
Underlying disease
Yes 256 (70.3) 108 (29.7) 1.185 (0.894 to 1.572) 0.237
No 503 (73.8) 179 (26.2) 1
Visual field defect severity‡
Severe 150 (68.2) 70 (31.8) 1.322 (0.941 to 1.856) 0.267
Moderate 138 (73.0) 51 (27.0) 1.047 (0.722 to 1.518)
Mild 422 (73.9) 149 (26.1) 1
Data were presented as n (%).
*Excluded two patients whose adherence was not reported.
†Mean±SD, median (first quartile, third quartile), Mann-Whitney U test.
‡Excluded patients with no report on disease severity (n=66).
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the study results can be used to establish a strong foundation to
develop strategies to improve glaucoma management through
enhancing medication adherence.
Nevertheless, there are some limitations to this study.
Medication adherence was evaluated by calculating the number
of days that the patient missed doses of eye-drops during the
previous 7 days through a self-reported questionnaire. Hence,
there is a possibility of reporting error resulted by recall bias of
responders. This is a fundamental limitation of using self-
reported questionnaires, despite which they are widely used in
many epidemiological studies. Moreover, it is somewhat compli-
cated to identify direct causal relationships between medication
adherence and characteristics and habits of administration of the
patients because of the cross-sectional nature of this study.
Another problem limitation is that the level of patients’ knowl-
edge of the disease, which is thought to greatly inﬂuence adher-
ence, was not evaluated. On the other hand, these study results
are still promising in terms of observing the risk factors, that is,
males and increased number of daily instillation to non-
adherence from a large number of patients.
Nonetheless, considering that this study targeted a large
number of patients, the results are thought to be signiﬁcant in
that it found that the risk of non-adherence was increased in
males, and, furthermore, that non-adherence increased with fre-
quency of topical administration of eye-drops, regardless of the
level of patient knowledge.
In conclusion, the proportion of patients who were adherent
to glaucoma medications in South Korea was about 70%, which
is considered to be relatively good. However, remaining 30%
were still non-adherent to glaucoma therapy, and the non-
adherent rate of glaucoma medication was greater in males and
when the prescribed frequency of administration was increased,
so special attention should be paid to those patient populations.
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